PF-Atlas › Clinical Trials › NCT01557322
Characterize Patients With Moderately Active Rheumatoid Arthritis
etanercept · Not specified
Registry ID
NCT01557322
Phase
Not specified
Status
Completed
Drug / intervention
etanercept
Sponsor
Pfizer
Start
2011-10
Enrollment
1754
About this trial
1. To assess the baseline (i.e. RA therapy initiation) characteristics in a real-world setting across two moderate RA cohorts: a Test Group of patients newly exposed to etanercept (Enbrel) therapy and a Control Group of patients with similar disease characteristics newly exposed to other, non-biologic therapies. 2. To assess the change over time (from baseline to the most recent follow-up) in the characteristics described at baseline in 2 British Society for Rheumatology Biologics Register (BSRBR) cohorts (i.e. moderate RA patients treated with Disease modifying anti-rheumatic drugs (DMARDs) alone versus moderate RA patients treated with Enbrel).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01557322 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.